Cargando…

Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis

BACKGROUND: Extrapulmonary tuberculosis (EPTB) and most pediatric TB cannot be diagnosed using sputum-based assays. The epidemiological impact of different strategies to diagnose EPTB and pediatric TB is unclear. METHODS: We developed a dynamic epidemic model of TB in a hypothetical population with...

Descripción completa

Detalles Bibliográficos
Autores principales: Denkinger, Claudia M, Kampmann, Beate, Ahmed, Syed, Dowdy, David W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168123/
https://www.ncbi.nlm.nih.gov/pubmed/25186052
http://dx.doi.org/10.1186/1471-2334-14-477
_version_ 1782335489923088384
author Denkinger, Claudia M
Kampmann, Beate
Ahmed, Syed
Dowdy, David W
author_facet Denkinger, Claudia M
Kampmann, Beate
Ahmed, Syed
Dowdy, David W
author_sort Denkinger, Claudia M
collection PubMed
description BACKGROUND: Extrapulmonary tuberculosis (EPTB) and most pediatric TB cannot be diagnosed using sputum-based assays. The epidemiological impact of different strategies to diagnose EPTB and pediatric TB is unclear. METHODS: We developed a dynamic epidemic model of TB in a hypothetical population with epidemiological characteristics similar to India. We evaluated the impact of four alternative diagnostic test platforms on adult EPTB and pediatric TB mortality over 10 years: (1) Nucleic acid amplification test optimized for diagnosis of EPTB (“NAAT-EPTB”); (2) NAAT optimized for pediatric TB (“NAAT-Peds”); (3) more deployable NAAT for sputum-based diagnosis of adult pulmonary TB (“point-of-care (POC) sputum NAAT”); and (4) more deployable NAAT capable of diagnosing all forms of TB using non-invasive, non-sputum specimens (“POC non-sputum NAAT”). RESULTS: NAAT-EPTB lowered adult EPTB mortality by a projected 7.6% (95% uncertainty range [UR]: 6.5-8.8%). NAAT-Peds lowered pediatric TB mortality by 6.8% (UR: 4.9-8.4%). POC sputum NAAT, though only able to diagnose pulmonary TB, reduced projected pediatric TB deaths by 13.3% (UR: 4.6-15.7%) and adult EPTB deaths by 8.4% (UR 2.0-9.3%) simply by averting transmission of disease. POC non-sputum NAAT had the greatest effect, lowering pediatric TB mortality by 34.7% (UR: 26.8-38.7), and adult EPTB mortality by 38.5% (UR: 30.7-41.2). The relative impact of a POC sputum NAAT (i.e., enhanced deployability) versus NAAT-EPTB (i.e., enhanced ability to specifically diagnose TB-NSP) on adult EPTB mortality depends most strongly on factors that influence transmission, with settings of higher transmission (e.g., higher per-person transmission rate, lower diagnostic rate) favoring POC sputum NAAT. CONCLUSION: Although novel tests for pediatric TB and EPTB are likely to reduce TB mortality, major reductions in pediatric and EPTB incidence and mortality also require better diagnostic tests for adult pulmonary TB that reach a larger population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-477) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4168123
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41681232014-09-20 Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis Denkinger, Claudia M Kampmann, Beate Ahmed, Syed Dowdy, David W BMC Infect Dis Research Article BACKGROUND: Extrapulmonary tuberculosis (EPTB) and most pediatric TB cannot be diagnosed using sputum-based assays. The epidemiological impact of different strategies to diagnose EPTB and pediatric TB is unclear. METHODS: We developed a dynamic epidemic model of TB in a hypothetical population with epidemiological characteristics similar to India. We evaluated the impact of four alternative diagnostic test platforms on adult EPTB and pediatric TB mortality over 10 years: (1) Nucleic acid amplification test optimized for diagnosis of EPTB (“NAAT-EPTB”); (2) NAAT optimized for pediatric TB (“NAAT-Peds”); (3) more deployable NAAT for sputum-based diagnosis of adult pulmonary TB (“point-of-care (POC) sputum NAAT”); and (4) more deployable NAAT capable of diagnosing all forms of TB using non-invasive, non-sputum specimens (“POC non-sputum NAAT”). RESULTS: NAAT-EPTB lowered adult EPTB mortality by a projected 7.6% (95% uncertainty range [UR]: 6.5-8.8%). NAAT-Peds lowered pediatric TB mortality by 6.8% (UR: 4.9-8.4%). POC sputum NAAT, though only able to diagnose pulmonary TB, reduced projected pediatric TB deaths by 13.3% (UR: 4.6-15.7%) and adult EPTB deaths by 8.4% (UR 2.0-9.3%) simply by averting transmission of disease. POC non-sputum NAAT had the greatest effect, lowering pediatric TB mortality by 34.7% (UR: 26.8-38.7), and adult EPTB mortality by 38.5% (UR: 30.7-41.2). The relative impact of a POC sputum NAAT (i.e., enhanced deployability) versus NAAT-EPTB (i.e., enhanced ability to specifically diagnose TB-NSP) on adult EPTB mortality depends most strongly on factors that influence transmission, with settings of higher transmission (e.g., higher per-person transmission rate, lower diagnostic rate) favoring POC sputum NAAT. CONCLUSION: Although novel tests for pediatric TB and EPTB are likely to reduce TB mortality, major reductions in pediatric and EPTB incidence and mortality also require better diagnostic tests for adult pulmonary TB that reach a larger population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-477) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-03 /pmc/articles/PMC4168123/ /pubmed/25186052 http://dx.doi.org/10.1186/1471-2334-14-477 Text en © Denkinger et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Denkinger, Claudia M
Kampmann, Beate
Ahmed, Syed
Dowdy, David W
Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis
title Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis
title_full Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis
title_fullStr Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis
title_full_unstemmed Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis
title_short Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis
title_sort modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168123/
https://www.ncbi.nlm.nih.gov/pubmed/25186052
http://dx.doi.org/10.1186/1471-2334-14-477
work_keys_str_mv AT denkingerclaudiam modelingtheimpactofnoveldiagnostictestsonpediatricandextrapulmonarytuberculosis
AT kampmannbeate modelingtheimpactofnoveldiagnostictestsonpediatricandextrapulmonarytuberculosis
AT ahmedsyed modelingtheimpactofnoveldiagnostictestsonpediatricandextrapulmonarytuberculosis
AT dowdydavidw modelingtheimpactofnoveldiagnostictestsonpediatricandextrapulmonarytuberculosis